www.senology.org   -   Newsletter

"Join  the international senologic and oncologic  scientific community"

Gian Paolo Andreoletti, MD, Editor-in-Chief  -  paolo.andreoletti@senology.it

  Subscribe      Unsubscribe     Contact      Back Issues      www.senology.org / www.senology.it  Home Page

Literature Selection

Editorial

  • "The role of insulin-like growth factor-I (IGF-I)  in human breast cancer"- Adrian V. Lee,  Breast Center, Baylor College of Medicine, Houston, TX , USA
     
    "Substantial evidence implicates IGF-I signaling in the development of breast carcinoma. To more clearly elucidate the role of IGF-I in human breast cancer, we identified and examined gene expression patterns of IGF-I-treated breast cancer cells. IGF-I caused temporal changes in gene expression that were strongly associated with breast cell proliferation, metabolism, and DNA repair. The IGF-I signature was manifested in the majority of ER-negative breast tumors and in a subset of ER-positive tumors. Patients who had tumors that manifested the IGF-I signature (including patients who did not receive adjuvant therapy) had a shorter time to a poor outcome event. The IGF gene signature was highly correlated with numerous poor prognostic factors and was one of the strongest indicators of outcome. This data indicates that transcriptional targets of IGF-I represent pathways of increased aggressiveness and possibly hormone independence in human breast carcinoma"
    (Comment on paper:      Creighton CJ et al.: "Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis", J Clin Oncol. 2008 Sep 1;26(25):4078-85)

Press Releases

Calendar of Events

Literature Selection

Editorial

  • "Underlying cancers in patients with unprovoked venous-thromboembolism" - Marc Carrier, Marc Rodger,  University of Ottawa and Ottawa Health Research Institute, Ottawa, Ontario, Canada
     
    "Underlying cancers are frequent in patients with unprovoked venous-thromboembolism (VTE). One in 10 patients will be diagnosed with a cancer within 12 months following the VTE. All patients with a newly diagnosed unprovoked VTE should have a complete medical history, physical examination, basic blood work (including complete blood count, liver function tests, renal function tests and calcium) and a chest X ray. Physicians should make sure that their patients are up to date regarding breast, cervical, colon and prostate cancer screening (according to National Guidelines). Any abnormalities on the above tests should be investigated as appropriate. It is still unclear if any other (or more extensive) tests should be performed on all patients with unprovoked VTE. Decision should be made on an individual basis after assessing the patient. If further test is warranted then computed tomography (CT) of the abdomen/pelvis provides the best yield of underlying malignancy detection. However, although CT abdomen/pelvis finds more cancers, it is unknown if this will translate into a better clinical outcomes (increased survival and quality of life) for patients"
    (Comment on paper:      Carrier M et al.: "Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism?", Ann Intern Med. 2008 Sep 2;149(5):323-33)

Press Releases


Literature Selection

Educational Grants - Sincere appreciation is extended to the following companies for their generous support of this activity:
- Roche
- AstraZeneca

If this e-mail has reached you in error, simply click on the following link and unsubscribe yourself:  Unsubscribe

Contact info - For advertising information please contact: A&B@senology.it . For other enquiries, problems or suggestions please contact: staff@senology.it

© A&B Edizioni Medico-Scientifiche - Milan,  Italy.  Fax: +39.035.738803